# IBI130

Source: https://onco.cc/drugs/ibi130/  
OnCo record `ibi130` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IBI130 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.

## Summary

ASCO 2025 abstract 1102 reports 71 patients treated in the first-in-human study at the December 15, 2024 cutoff. Among 30 efficacy-evaluable TNBC patients across doses, ORR was 50.0% (95% CI 31.3 to 68.7); PFS and duration of response were immature. Grade 3 treatment-related events occurred in 15.5% of the 71 patients; one had grade 1 interstitial lung disease. This is an uncontrolled early cohort, not comparative proof of improved safety or efficacy.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: ADC
- Mechanism: Anti-TROP2 antibody linked to NT1, a camptothecin-derived TOP1 inhibitor.
- Payload: NT1 (camptothecin derivative, TOP1 inhibitor)

## Sources

- Publisher abstract: https://doi.org/10.1200/jco.2025.43.16_suppl.1102
- ClinicalTrials.gov NCT05923008: https://clinicaltrials.gov/study/NCT05923008

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05923008/)

---
JSON: https://onco.cc/api/v1/entities/ibi130.json